You are here

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Can IL-1 be used as a target for osteoarthritis?’ by Cheng et al
Free
  1. Margreet Kloppenburg1,
  2. Marc Levesque2
  1. 1 Rheumatology, LUMC, Leiden, The Netherlands
  2. 2 Immunology Development, AbbVie, North Chicago, Illinois, USA
  1. Correspondence to Professor Margreet Kloppenburg, Rheumatology, LUMC, Leiden 2300 RC, Netherlands; g.kloppenburg{at}lumc.nl

https://doi.org/10.1136/annrheumdis-2019-215612

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Cheng, Tian and Zhang1 for their interest in our article2 that showed that targeting interleukin (IL)-1α and IL-1β with lutikizumab did not significantly improve clinical and imaging outcomes in patients with inflammatory erosive hand osteoarthritis (HOA). The results of the study were indeed disappointing and, appropriately, should stimulate discussion about the role of IL-1 in osteoarthritis.

    In our trial, levels of IL-1 were significantly reduced in subjects with erosive HOA and moderate to severe inflammation indicated by joint swelling, joint pain and synovitis.1 Although levels of IL-1 were not measured after week 4 of treatment, other biomarkers (eg, …

    View Full Text

    Linked Articles